التفاصيل البيبلوغرافية
| العنوان: |
Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. |
| المؤلفون: |
Erzurum, Serpil C., Leff, Jonathan A., Cochran, Judith Evans, Ackerson, Lynn M., Szefler, Stanley J., Martin, Richard J., Cott, Gary R., Erzurum, S C, Leff, J A, Cochran, J E, Ackerson, L M, Szefler, S J, Martin, R J, Cott, G R |
| المصدر: |
Annals of Internal Medicine; 3/1/91, Vol. 114 Issue 5, p353-360, 8p |
| مصطلحات موضوعية: |
METHOTREXATE, ASTHMATICS |
| مستخلص: |
Objective: To determine the effect of low-dose methotrexate in asthmatic patients on steroid use, asthma symptom scores, pulmonary function, airway reactivity, blood cellular components, and immunoglobulin E levels.Design: A randomized, double-blind, parallel, placebo-controlled, 13-week clinical trial with follow-up of patients in an open trial of methotrexate at the conclusion of the double-blind study.Setting: An asthma care outpatient clinic.Patients: From February 1988 to March 1990, 19 patients with severe, steroid-dependent asthma were enrolled in the study. Two of these patients were excluded from analysis.Interventions: Patients were administered methotrexate or placebo intramuscularly, to assure complete absorption, once weekly during the 13-week study.Results: Patients on methotrexate and placebo both significantly decreased their steroid dose by 39.6% (95% CI, 25.1% to 54.1%, P = 0.001) and 40.2% (CI, 17.9% to 67.4%, P = 0.003), respectively. Pulmonary function did not differ significantly between the methotrexate and placebo groups. In addition, airway reactivity and symptom scores were unchanged on methotrexate or placebo. No significant toxicities were seen during the course of the 13-week blinded study, but one patient on methotrexate and prednisone in the follow-up period developed Pneumocystis carinii pneumonia and died. Despite continuing methotrexate for up to 1 year, and increasing methotrexate to 30 mg weekly, no significant benefit of methotrexate on asthma control could be shown.Conclusion: Our study does not support the use of methotrexate in the treatment of severe asthma. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
